Irbesartán/Hidroclorotiazida Pensa

Irbesartan and Hydrochlorothiazide, the active ingredients in Irbesartán/Hidroclorotiazida Pensa, are an angiotensin II receptor blocker and a thiazide diuretic presented as oral tablets for oral use. They are indicated for the management of hypertension in adult patients.

GNH USA supplies Irbesartán/Hidroclorotiazida Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to lower blood pressure.

Essential hypertension: reduces systolic and diastolic pressure by vasodilation and volume depletion. Secondary hypertension: provides effective control when hypertension is due to underlying conditions. Hypertension requiring combination therapy: offers dual mechanism to achieve target blood pressure when monotherapy is insufficient.

The combination may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration - Acute kidney injury - Hyperkalemia - Angioedema - Severe hypotension - Allergic skin reactions (e.g., Stevens‑Johnson syndrome)

When prescribing Irbesartan/Hydrochlorothiazide, clinicians should observe several safety considerations.

Blood pressure monitoring: check regularly to avoid excessive hypotension. Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics. Diabetes caution: may affect glucose control; monitor blood sugar. Pregnancy and lactation: use only if potential benefit justifies risk, as safety data are limited. Store at below 25°C: keep in original packaging, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren: combined use may increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors or other ARBs: additive effects on blood pressure and potassium.

Moderate Interactions (Monitor Closely): - NSAIDs: can reduce antihypertensive effect and impair renal function. - Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment.